The Anti-fibrotic Actions of Relaxin Are Mediated Through a NO-sGC-cGMP-Dependent Pathway in Renal Myofibroblasts In Vitro and Enhanced by the NO Donor, Diethylamine NONOate
Chao Wang(Monash University), Chrishan S. Samuel(Monash University)
Cited by 40
Related Papers
Relaxin Signals through a RXFP1-pERK-nNOS-NO-cGMP-Dependent Pathway to Up-Regulate Matrix Metalloproteinases: The Additional Involvement of iNOS
|PLoS ONE|2012|129
Antifibrotic Properties of Relaxin: In Vivo Mechanism of Action in Experimental Renal Tubulointerstitial Fibrosis
|Endocrinology|2010|72
AT1R-AT2R-RXFP1 Functional Crosstalk in Myofibroblasts: Impact on the Therapeutic Targeting of Renal and Cardiac Fibrosis
|Journal of the American Society of Nephrology|2019|49
Relaxin Can Mediate Its Anti-Fibrotic Effects by Targeting the Myofibroblast NLRP3 Inflammasome at the Level of Caspase-1
|Frontiers in Pharmacology|2020|33
Comparing the renoprotective effects of BM-MSCs versus BM-MSC-exosomes, when combined with an anti-fibrotic drug, in hypertensive mice
|Biomedicine & Pharmacotherapy|2021|18